GlassScriptPhysician profile
James B Malone
NPI 1295920163
$3,873.61
in general payments reported to CMS, 2019-2025
41 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $491 · 2021: $548 · 2022: $545 · 2023: $651 · 2024: $511 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $522.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $377.94 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $290.85 | 2019-2024 | |
| Novo Nordisk INC | $273.55 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $228.58 | 2019-2024 | Veozah |
| Pfizer INC. | $190.65 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.70 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.67 | 2020-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $129.72 | 2019-2023 | |
| Lilly USA, LLC | $126.19 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $122.69 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $109.79 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $97.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.74 | 2020-2022 | |
| Eisai INC. | $93.91 | 2020-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.